Earl S. Ford, MD, MPH Background-Little is known about trends in the mortality rate among people with hypertension in the United States. The objective of the present study was to examine the change in the all-cause mortality rate among people with and without hypertension in the United States and whether any such changes differed by sex or race. Methods and Results-Data from 10 852 participants aged 25 to 74 years of the National Health and Nutrition Examination Survey (NHANES) I Epidemiological Follow-Up Study (1971 to 1975) and of 12 420 participants of the NHANES III Linked Mortality Study (1988 to 1994) were used. The mean follow-up times were 17.5 and 14.2 years, respectively. In each cohort, the mortality rate was higher among hypertensive adults than nonhypertensive adults, among hypertensive men than hypertensive women, and among hypertensive blacks than hypertensive whites. Among all hypertensive participants, the age-adjusted mortality rate was 18.8 per 1000 person-years for NHANES I and 14.3 for NHANES III (13.3 and 9.1 per 1000 person-years for nonhypertensive participants, respectively). The reduction among hypertensive men (7.7 per 1000 person-years; 95% confidence interval, 5.2 to 10.2) exceeded that among hypertensive women (1.9 per 1000 person-years; 95% confidence interval, [Ϫ0.4 to 4.2]) (PϽ0.001), and the reduction among hypertensive blacks (5.4 per 1000 person-years; 95% confidence interval, [0.6 to 10.1]) exceeded that among hypertensive whites (4.4 per 1000 person-years; 95% confidence interval, [2.2 to 6.5]) (Pϭ0.707). Conclusions-The mortality rate decreased among hypertensive adults, but the mortality gap between adults with and without hypertension remained relatively constant. Efforts are needed to accelerate the decrease in the mortality rate among hypertensive adults. (Circulation. 2011;123:1737-1744.)
H igh blood pressure is an important preventable cause of mortality, and accounts for a substantial portion of global burden of disease. 1, 2 In the United States, hypertension is a common condition, with estimates suggesting that 29% of adults Ն18 years of age had hypertension during the period 2007 to 2008, a percentage not much changed from the estimate of 28.5% during 1988 to 1994. 3 Furthermore, this condition is a common reason for office visits. 4 People with hypertension have higher rates of mortality than people without hypertension, particularly of vascular mortality. 5, 6 Because of the high prevalence of this condition and the increased morbidity and mortality associated with this condition, the economic cost of hypertensive disease was estimated at $76.6 billion in 2010. 7 
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For the field of hypertension, the latter part of the 20th century was a dynamic period, with the growth of an enormous arsenal of antihypertensive medications and, as a result of the National High Blood Pressure Education Program and other efforts, 8 steady improvements in hypertension detection and control in the United States. 3, 9, 10 These developments should have translated into reductions in the mortality rate among people with hypertension. However, little is known about trends in the mortality rate of such people. Therefore, the objective of this study was to examine the change in mortality from all causes and from cardiovascular disease among people with and without hypertension in the United States and to examine whether any such changes differed by sex or race or ethnicity.
Methods
This study included data from the National Health and Nutrition Examination Survey (NHANES) I Epidemiological Follow-Up Study (1971 to 1975) and the NHANES III Linked Mortality Study (1988 to 1994). 11, 12 For the baseline surveys, participants were selected by use of a stratified multistage probability sample. Stages of selection included primary sampling units, segments, households, and sample persons. 13, 14 After an interview in the home, participants were invited for an examination in the mobile examination center, where they were asked to complete additional questionnaires, to undergo various examinations, and to provide a blood sample. Both record linkage studies received approval from the National Center for Health Statistics Research Ethics Review Board.
National Health and Nutrition Examination Survey I participants were followed up through 1992, and NHANES III participants were followed up through 2006. Attempts were made to contact NHANES I participants during 1982 to 1984, 1985, 1986, and 1992 . National Health and Nutrition Examination Survey III participants were not contacted. The records of both cohorts were matched against the National Death Index to identify deaths. For NHANES I participants, other tracing methods were also used to establish vital status. A calibration study using the NHANES I Epidemiological Follow-Up Study reported that the National Death Index correctly classified the vital status of 98.5% of participants in the cohort. 15 Death certificates were obtained for deceased participants, and the following codes for the underlying cause of death were used to define specific causes of death: diseases of the circulatory system (International Classification of Diseases, 9th Revision (ICD-9) and major cardiovascular disease (International Classification of Diseases, 10th Revision (ICD-10): ICD-9 codes 390 to 458 and ICD-10 codes I00 to I78; ischemic heart disease: ICD-9 codes 410 to 414 and ICD-10 codes I20 to I25; and stroke: ICD-9 codes 430 to 438 and ICD-10 codes I60 to I69.
Hypertension was defined as a systolic blood pressure Ն140 mm Hg or a diastolic blood pressure Ն90 mm Hg or the current use of antihypertensive medication. Differences in the protocols for measuring blood pressure for the 2 surveys have been summarized elsewhere. 9 A single blood-pressure measurement was obtained in NHANES I, whereas up to 3 such measurements were obtained in NHANES III. To maintain consistency across cohorts, only the first blood pressure measurement was used to classify NHANES III participants. The current use of antihypertensive medication was determined from the question, "During the past 6 months have you used any medicine, drugs, or pills for any of the following: high blood pressure" in NHANES I and from the question, "Are you now taking prescribed medicine?" in NHANES III.
Covariates in the analyses included age, sex, race or ethnicity, educational achievement, smoking status, concentrations of total cholesterol, body mass index, and histories of diabetes mellitus, myocardial infarction, stroke, and congestive heart failure. Mortality rates per 1000 person-years were calculated. For NHANES I participants, the number of person-years of follow-up time was calculated from the time of entry into the study until the date of death, termination date of the study, or date of last known contact. For NHANES III participants, the number of person-years of follow-up time was calculated from the time of entry into the study until date of death or the termination date of the study. Age adjustment using the direct method was performed by using the distribution of the projected US population 25 to 74 years of age in the year 2000. Differences in rates were tested by using t tests. Race-specific analyses were restricted to whites and blacks, because only these 2 groups were available in NHANES I. Analyses were conducted with SUDAAN software to account for the complex sampling designs of the surveys.
Results
The National Health and Nutrition Examination Survey I Epidemiological Follow-Up Study was composed of several different samples. The sample comprising 11 348 participants was used. Of these participants in NHANES I, 10 852 participants were included in the analyses after excluding participants with age Ͻ25 and Ͼ74 years (nϭ24), and with missing data for mortality status (nϭ423) and hypertension status (nϭ51). Of the 12 841 participants 25 to 74 years of age in NHANES III who attended the mobile examination center, 12 420 participants were included in the analyses after excluding participants with missing data for mortality status (nϭ10) and hypertension status (nϭ411). Sample sizes were further reduced for some analyses that included other study variables.
The age-adjusted prevalence of hypertension in the eligible study population was 43.0% in NHANES I and 26.1% in NHANES III. With a few exceptions, the direction and significance of changes in the sociodemographic variables and risk factors from NHANES I to NHANES III were similar among participants with and without hypertension ( Table 1 and online-only Data Supplement Table I ). Among risk factors, significant favorable changes were noted for the prevalence of current smoking and mean blood pressure and for mean concentrations of total cholesterol. Significant adverse changes were noted for mean body mass index and the prevalence of having a history of diabetes mellitus.
All-Cause Mortality
The mean follow-up times were 17.5 years for NHANES I and 14.2 years for NHANES III. The numbers of deaths were 3963 (2859 among participants with hypertension and 1104 among participants without hypertension) in NHANES I and 2346 (1346 among participants without hypertension and 1000 among participants without hypertension) in NHANES III. Mortality among participants with hypertension was about 42% higher in NHANES I (18.8 versus 13.3 per 1000 person-years, PϽ0.001) and about 57% higher in NHANES III (14.3 versus 9.1 per 1000 person-years, PϽ0.001) relative to participants without hypertension. Furthermore, the mortality rate was higher among hypertensive men than hypertensive women during both studies (NHANES I: 23.5 versus 15.0 per 1000 person-years, PϽ0.001; NHANES III: 15.7 versus 13.2 per 1000 person-years, Pϭ0.025).
The decline in the overall mortality rate masked gender differences. Among participants with hypertension, mortality declined by 7.7 (95% confidence interval [CI]: 5.2 to 10.2) per 1000 person-years, reflecting a relative reduction of 33%, among men and by 1.9 (95% CI: Ϫ0.4 to 4.2) per 1000 person-years, reflecting a relative reduction of 12%, among women (P difference Ͻ0.001). For participants with a systolic blood pressure Ն180 mm Hg or a diastolic blood pressure Ն110 mm Hg, the age-adjusted mortality rate changed little ( Figure 1 ). A nonsignificant decrease in the mortality rate was observed among men, and a nonsignificant increase was observed among women.
Among participants with hypertension, the mortality rate among black participants exceeded that among white participants in both cohorts (NHANES I: 24.5 versus 18.1 per 1000 person-years, Pϭ0.004; NHANES III: 19.1 versus 13.7 per 1000 person-years, PϽ0.001) ( Figure 2 ). The mortality rate decreased by 4.4 (95% CI: 2.2 to 6.5) per 1000 person-years among white participants and by 5.4 (95% CI: 0.6 to 10.1) per 1000 person-years among black participants (P differ-enceϭ0.707), and thus the mortality gap between white and black hypertensive participants narrowed from 6.4 per 1000 person-years to about 5.4 per 1000 person-years.
Cardiovascular Disease
In NHANES I, 1992 deaths were attributed to diseases of the circulatory system or major cardiovascular disease (1557 among adults with hypertension and 435 among people without hypertension), 1113 deaths were attributed to ischemic heart disease (851 among adults with hypertension and 262 among people without hypertension), and 366 deaths were attributed to stroke (296 among adults with hypertension and 70 among people without hypertension). In NHANES III, 897 deaths were attributed to disease of the circulatory system or major cardiovascular disease (578 among adults with hypertension and 319 among people without hypertension), 515 deaths were attributed to ischemic heart disease (327 among adults with hypertension and 188 among people without hypertension), and 138 deaths were attributed to stroke (98 among adults with hypertension and 40 among people without hypertension).
In each cohort, adults with hypertension had significantly higher mortality rates for diseases of the circulatory system (PϽ0.001 for both cohorts), ischemic heart disease (PϽ0.001 for NHANES I and 0.002 for NHANES III), and stroke (PϽ0.001 for NHANES I and 0.005 for NHANES III) than adults without hypertension ( Table 2 ). The same pattern prevailed among men (all PϽ0.05). Compared to women without hypertension, women with hypertension had significantly or borderline significantly higher mortality rates for diseases of the circulatory system in each cohort (PϽ0.001 for NHANES I and 0.004 for NHANES III) and stroke in NHANES I (PϽ0.001 for NHANES I and 0.061 for NHANES III) but not ischemic heart disease.
The absolute mortality rate for diseases of the circulatory system dropped by 3.6 per 1000 person-years among all adults with hypertension and 2.6 per 1000 person-years among those without hypertension, by 5.5 per 1000 personyears among men with hypertension, by 3.1 per 1000 personyears among men without hypertension, by 1.6 per 1000 person-years among women with hypertension, and by 2.2 per 1000 person-years among women without hypertension. The decrease in the mortality rate among hypertensive men differed significantly from that among hypertensive women (Pϭ0.008). Thus, the mortality gap for diseases of the circulatory system tended to shrink between hypertensive men and women. Furthermore, the mortality gap between hypertensive and nonhypertensive participants shrank among men but widened among women.
Among adults with hypertension, blacks had significantly higher mortality rates for diseases of the circulatory system 
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(NHANES I: Pϭ0.023; NHANES III: Pϭ0.043) and stroke (P NHANES Iϭ0.004; P NHANES IIIϭ0.050) in both cohorts than whites ( Table 3 ). The absolute mortality rate for diseases of the circulatory system decreased by 3.1 per 1000 person-years among whites with hypertension, by 2.6 per 1000 person-years among whites without hypertension, by 5.2 per 1000 person-years among blacks with hypertension, and by 2.7 per 1000 person-years among blacks without hypertension. However, the reductions in the mortality rate among hypertensive participants did not differ significantly by race (Pϭ0.309). The mortality gap between adults with and without hypertension changed little among whites but, among blacks, decreased from 6.1 per 1000 person-years to 3.6 per 1000 person-years, and the mortality gap between whites and blacks with hypertension shrank from 4.0 per 1000 person-years to 1.9 per 1000 person-years.
Discussion
The results from these analyses offer a mix of welcome and troublesome findings. The former include the reduction in the age-adjusted mortality rate among people with hypertension by 4.6 per 1000 person-years (although comparable to the decrease of 4.2 per 1000 person-years among people without hypertension), the narrowing of the mortality gap between hypertensive men and women, and the decline in the mortality rate among hypertensive blacks, which led to a narrowing of the mortality gap with hypertensive whites. More troublesome is the somewhat subpar decrease in the mortality rate among hypertensive women that resulted in a widening of the mortality gap with women without hypertension. Conceivably, at least 2 broad currents should have impacted the mortality rate among people with hypertension: the improvements in the detection, treatment, and control of hypertension, 3, 9, 10 and a set of factors not specifically related to hypertension driving the secular decline in mortality in the population at large. Cohort studies show that participants with uncontrolled hypertension have a higher rate of mortality than participants with controlled hypertension. 16 -18 Furthermore, community studies have also demonstrated the potential to reduce mortality attributable to elevated blood pressure by improving hypertension control. 19, 20 Reductions in the prevalence of current smokers and in the means of systolic blood pressure and total cholesterol accounted for a large proportion of the decline in the mortality rate from coronary heart disease in the United States from 1980 to 2000. 21 If hypertensive adults had benefitted equally from secular changes that affected the mortality rate in the general population as adults without hypertension, one might have anticipated that improvements in hypertension treatment and control would have accelerated the decline in the mortality rate among people with hypertension and narrowed the mortality gap between those with and without hypertension. The apparent persistence of the mortality gap in the face of improving hypertension treatment and control suggests that the factors driving the mortality rate in the general population may have had less impact on those with hypertension. The results in Table 1 may provide some insights in this regard. Changes in some of the risk factors were less favorable in hypertensive participants. Mean total cholesterol decreased by 0.18 mmol/L among hypertensive participants and by 0.33 mmol/L among nonhypertensive participants, mean body mass index increased by 2.2 kg/m 2 among hypertensive participants, on top of an already high mean body mass index, and by 1.7 kg/m 2 among nonhypertensive participants, and the prevalence of diagnosed diabetes mellitus increased by an absolute 5.4% among hypertensive participants and by 1.5% among nonhypertensive participants. Hypertensive participants experienced a somewhat larger absolute reduction in the prevalence of smoking (12.8% versus 10.1%). Thus, the balance of these changes in important risk factors for cardiovascular disease may indicate that hypertensive adults benefitted less from the secular changes that affected mortality from cardiovascular disease during the study period. Consequently, controlling cardiovascular risk factors in adults with hypertension is of paramount importance in reducing mortality from all causes and from cardiovascular disease. The relatively small drop in the mortality rate among women with hypertension both with respect to men with hypertension and to women without hypertension was unexpected and requires confirmation. Using thresholds of 160/ 95 mm Hg to define hypertension, Burt et al reported that the percentage of men 18 to 74 years of age who received treatment increased from 29% in NHANES I to 72% in NHANES III, and of women from 45% in NHANES I to 86% in NHANES III. 9 Control increased from 43% to 80% among treated men and from 42% to 84% among treated women. Using blood-pressure thresholds of 140/90 mm Hg to define hypertension, Egan et al reported steady improvements in treatment and control from NHANES III to NHANES 2007 to 2008. 3 Although the percentage of women receiving treatment was slightly higher than that among men during 2007 to 2008, the percentage of hypertensive adults who had controlled hypertension was similar. In the absence of influ-ences other than management of hypertension, the improvements in hypertension treatment and control and the erasure of gender differences in these parameters may help to explain the narrowing of the mortality gap between hypertensive men and women. Despite the more modest declines in the mortality rate among hypertensive women than men, the decreases in mean systolic blood pressure and diastolic blood pressure in women outstripped those in men. Furthermore, hypertensive women experienced larger increases in mean body mass index and in diagnosed diabetes mellitus than men, but hypertensive men experienced a much larger decrease in smoking than hypertensive women. The complicated interplay of the trends in these as well as other unmeasured factors ultimately governed the mortality trajectories.
Although the mortality rate among hypertensive blacks was higher than that among hypertensive whites in both cohorts, there was some narrowing of the mortality gap 
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Trends in Mortality Among Adults With Hypertension between the 2 groups. On the basis of a definition of hypertension that used blood-pressure thresholds of 160/ 95 mm Hg, the percentages of whites and blacks who were treated and had controlled hypertension improved from NHANES I to NHANES III. 9 Additional improvements in hypertension treatment and control among both whites and blacks were noted in surveys using the more current definition of hypertension conducted during the period from 1999 to 2008. 3 These later surveys showed that a higher percentage of blacks than whites received treatment but that hypertension control was similar in the 2 groups. Thus, some of the narrowing of the mortality gap between hypertensive blacks and whites may reflect the attainment of similar control of hypertension in the 2 groups. The possible contribution of changes in risk factors to the narrowing of the mortality gap is less clear. Blacks with hypertension experienced a larger fall in concentrations of total cholesterol than whites with hypertension, but had larger increases in histories of diabetes mellitus and cardiovascular events than whites. The baseline results from NHANES III show that hypertensive blacks experienced significantly higher levels of systolic and diastolic blood pressure as well as a higher prevalence of diagnosed diabetes mellitus and smoking than hypertensive whites, suggesting important opportunities to further lower the mortality rate in blacks and narrow the mortality gap with whites.
Few studies have examined trends in mortality among people with hypertension. Among participants with long-term sustained hypertension in the Framingham Study, the allcause mortality rates in 3 successive cohorts 10 years apart (1950, 1960, and 1970) were 63, 40, and 38 per 1000 persons among men with long-term treatment, 58, 42, and 48 among men without long-term treatment, 32, 27, and 27 per 1000 persons among women with long-term treatment, and 36, 35, and 38 among women without long-term treatment. 22 Before 1980, hypertensive patients seen at a blood pressure clinic in Glasgow, Scotland, had greater than twice the mortality rate than several control groups. 23 After 1980, mortality declined, and the gap with the control groups narrowed. Several explanations for the decline were entertained, including that hypertensive patients benefitted from secular decreases in cardiovascular risk, improved control of blood pressure, and the uptake of certain classes of antihypertensive agents. Mortality among hypertensive adults living in Ontario, Can- ada, decreased from 1995 to 2005, with the declines among men exceeding those among women. 24 Also, in agreement with the present study, mortality among hypertensive men was higher than that among hypertensive women.
Strengths of the present study include nationally representative samples of adults in the United States, substantial sample sizes, and lengthy follow-up periods. However, the results of the present study should be interpreted in light of several considerations. First, the protocols for measuring blood pressure in NHANES evolved over time and may have resulted in inconsistent assignment of hypertension status. Also, the wording of the questions pertaining to the current use of antihypertensive medications differed somewhat between the baseline surveys.
Second, blood pressure was measured on a single occasion, and the diagnosis of hypertension requires an elevated blood pressure measured on at least 2 separate occasions. 25 Thus, some degree of misclassification of hypertensive status occurred. If a similar percentage of participants in NHANES I and NHANES III were misclassified, the absolute reductions in the age-adjusted mortality rate would have been unaffected, but the mortality gap between hypertensive and nonhypertensive participants in each cohort would have been underestimated. However, the change in this mortality gap would not have been affected. If a higher percentage of participants in NHANES I than in NHANES III were misclassified, the absolute reductions in the mortality rate among hypertensive participants as well as the change in the mortality gap between hypertensive and nonhypertensive participants in each cohort would have been underestimated.
Third, the prevailing definition of hypertension during the period when NHANES I was being conducted was based on thresholds of 160 mm Hg for systolic blood pressure and 95 mm Hg for diastolic blood pressure. 26 In 1980, this changed to 140 mm Hg and 90 mm Hg. 27 Thus, participants with hypertension in the range of a systolic blood pressure of 140 to 159 mm Hg or a diastolic blood pressure in the range of 90 to 95 mm Hg at the time when NHANES I was conducted were probably not being treated, and the mortality rate for these individuals may have been higher had subsequent definitions of hypertension been in effect during 1971 to 1975.
Fourth, information for some risk factors was incompletely measured (eg, smoking in NHANES I), was not measured in NHANES I (high-density lipoprotein cholesterol, C-reactive protein, and hemoglobin A1c), or was inconsistently measured across surveys (eg, physical activity). Furthermore, the wording for questions about diagnosed diabetes mellitus, myocardial infarction, stroke, and heart failure differed slightly between the 2 cohorts.
Fifth, changes in tests used to diagnose outcomes such as myocardial infarction and stroke evolved over time. For example, computed tomography scans and magnetic resonance imaging have been increasingly used to diagnose brain pathology, and the results of these tests were part of the clinical information used to assign causes of death by the participants' physicians.
In conclusion, declines in mortality among hypertensive adults in the United States generally paralleled those of adults without hypertension. Consequently, the mortality gap between all adults with and without hypertension persisted. However, declines in the mortality rate among women with hypertension were smaller than declines among men. Because little is apparently known about trends in the mortality rate among people with hypertension in the United States, additional research is needed to confirm the findings of the present study. If a gender difference in mortality trends is corroborated, the reasons for such a difference need to be elucidated. The results of the present study suggest that an increased focus on reducing mortality among hypertensive women is needed and that continued efforts to reduce the mortality gap between hypertensive men and women and between hypertensive whites and blacks are needed. Additional improvements in the detection and control of hypertension and careful attention to minimizing the prevalence of risk factors for chronic disease should help to further reduce mortality among people with hypertension.
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